ePrints

Cancer nanomedicine and the complement system activation paradigm: Anaphylaxis and tumour growth

Lookup NU author(s): Professor Moein MoghimiORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

A wide variety of nanocarriers and particularly cancer nanomedicines activate the complement system, which is the first line of the innate immune defence mechanism. Complement activation may induce inflammatory responses, but such responses arising from uncontrolled complement activation could be life threatening. Accordingly, the role of complement in initiation of adverse reactions to particulate and polymer therapeutics is receiving increasing attention. Furthermore, the involvement of complement-activation products in promoting tumour growth has also been indicated. This could be of serious concern for development of cancer nanomedicines and cancer nanotechnology initiatives. These concepts are reviewed with preliminary evidence that intra-tumoural accumulation of model long circulating nanoparticles could promote tumour growth. © 2014 Elsevier B.V. All rights reserved.

Publication metadata

Author(s): Moghimi SM

Publication type: Article

Publication status: Published

Journal: Journal of Controlled Release

Year: 2014

Volume: 190

Pages: 556-562

Print publication date: 28/09/2014

Online publication date: 16/04/2014

Acceptance date: 29/03/2014

ISSN (print): 0168-3659

ISSN (electronic): 1873-4995

Publisher: Elsevier

URL: https://doi.org/10.1016/j.jconrel.2014.03.051

DOI: 10.1016/j.jconrel.2014.03.051

PubMed id: 24746624

Altmetrics

Share